The company says the test is also being considered for use in women undergoing fertility treatments. Endometriosis is three times more common among IVF patients, where early intervention can be crucial. With fertility treatments on the rise globally, the commercial implications of PromarkerEndo could be significant.

Professor Peter Rogers, a leading endometriosis researcher at the Royal Women’s Hospital, said the test could transform patient management. “A reliable blood test that detects early-stage disease would allow us to intervene earlier, particularly in fertility cases where delays can have lasting consequences,” Professor Rogers said.

The commercial rollout of PromarkerEndo is now squarely in sight, with Proteomics targeting an Australian launch in the third quarter of this year.

The company plans to use its existing direct-to-consumer channels while also tapping into general practitioners and women’s health specialists. Regulatory and clinical testing approvals are underway and patents are pending in all major jurisdictions.

PromarkerEndo now joins Proteomics International’s expanding arsenal of precision diagnostics, all powered by its cutting-edge Promarker platform. The fingerprick protein blood test is the same innovation behind the company’s PromarkerD test for diabetic kidney disease and PromarkerEso for oesophageal cancer.

With PromarkerEndo now in the final stages of real-world validation and garnering backing from the scientific and medical communities, Proteomics is on the cusp of a commercial win. Beyond that, it could be on the verge of also changing patients’ lives.

Is your ASX-listed company doing something interesting? Contact: mattbirney@bullsnbears.com.au